[
  {
    "ts": null,
    "headline": "Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate",
    "summary": "Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate",
    "url": "https://finnhub.io/api/news?id=b633842c952421d9de1ca80e5eaecb30ab84127e58c327e6ec01e3d702687c2b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750892889,
      "headline": "Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate",
      "id": 135532362,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b633842c952421d9de1ca80e5eaecb30ab84127e58c327e6ec01e3d702687c2b"
    }
  },
  {
    "ts": null,
    "headline": "Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity",
    "summary": "Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.",
    "url": "https://finnhub.io/api/news?id=054f12b359d010b4310d08ea300d2446f9ca2c144f2ff37d6623230817623850",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750874860,
      "headline": "Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity",
      "id": 135527952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.",
      "url": "https://finnhub.io/api/news?id=054f12b359d010b4310d08ea300d2446f9ca2c144f2ff37d6623230817623850"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is Going To Be A “Trillion-Dollar Market Cap,” Says Jim Cramer",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show. He is a fan of the firm not only due to its lead in the […]",
    "url": "https://finnhub.io/api/news?id=ca51a49ea085efe1d6b114d98a449985a1df69b5a8b2142c166d637390198fde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750868439,
      "headline": "Eli Lilly and Company (LLY) Is Going To Be A “Trillion-Dollar Market Cap,” Says Jim Cramer",
      "id": 135527953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show. He is a fan of the firm not only due to its lead in the […]",
      "url": "https://finnhub.io/api/news?id=ca51a49ea085efe1d6b114d98a449985a1df69b5a8b2142c166d637390198fde"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO): “How Could They Be So Far Behind?,” Wonders Jim Cramer",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date. Novo Nordisk A/S (NYSE:NVO) has struggled […]",
    "url": "https://finnhub.io/api/news?id=d28fa12025d5503c909cf2a8b33d344ec156775afd6dbe55ad860bcaa798bee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750868407,
      "headline": "Novo Nordisk A/S (NVO): “How Could They Be So Far Behind?,” Wonders Jim Cramer",
      "id": 135527954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date. Novo Nordisk A/S (NYSE:NVO) has struggled […]",
      "url": "https://finnhub.io/api/news?id=d28fa12025d5503c909cf2a8b33d344ec156775afd6dbe55ad860bcaa798bee8"
    }
  },
  {
    "ts": null,
    "headline": "NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study",
    "summary": "Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.",
    "url": "https://finnhub.io/api/news?id=c00813a70079ca6515480ec697b280cf9da913dba5a62c1cdbb0293b8cb70284",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750865400,
      "headline": "NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study",
      "id": 135527955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.",
      "url": "https://finnhub.io/api/news?id=c00813a70079ca6515480ec697b280cf9da913dba5a62c1cdbb0293b8cb70284"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk split puts Hims & Hers future in question",
    "summary": "Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?",
    "url": "https://finnhub.io/api/news?id=32c473ee0a18f80e836348d212dda19cfbcac1672639fd82d686f098abe0e09e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750856841,
      "headline": "Novo Nordisk split puts Hims & Hers future in question",
      "id": 135527956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?",
      "url": "https://finnhub.io/api/news?id=32c473ee0a18f80e836348d212dda19cfbcac1672639fd82d686f098abe0e09e"
    }
  },
  {
    "ts": null,
    "headline": "Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market",
    "summary": "Investing.com -- Citi reaffirmed its bullish view on Eli Lilly (NYSE:LLY) stock as it sees significant upside from orforglipron, the company’s once-daily oral obesity drug candidate.",
    "url": "https://finnhub.io/api/news?id=4cbbf850a53dde553b407e2ce9607b83159ceefc83607d5b2f74ff178c393ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750851179,
      "headline": "Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market",
      "id": 135527957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Citi reaffirmed its bullish view on Eli Lilly (NYSE:LLY) stock as it sees significant upside from orforglipron, the company’s once-daily oral obesity drug candidate.",
      "url": "https://finnhub.io/api/news?id=4cbbf850a53dde553b407e2ce9607b83159ceefc83607d5b2f74ff178c393ce7"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow",
    "summary": "Eli Lilly is grabbing the lead in the fast-growing diabetes drug market.  Eli Lilly (NYSE: LLY) has been on fire over the past two years.  The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might think it's too late to invest.",
    "url": "https://finnhub.io/api/news?id=9ffdfc09c36d7d3bf71f9062d8930b9a07cdedce5704d687264e103b4111478a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750845900,
      "headline": "3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow",
      "id": 135527958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is grabbing the lead in the fast-growing diabetes drug market.  Eli Lilly (NYSE: LLY) has been on fire over the past two years.  The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might think it's too late to invest.",
      "url": "https://finnhub.io/api/news?id=9ffdfc09c36d7d3bf71f9062d8930b9a07cdedce5704d687264e103b4111478a"
    }
  },
  {
    "ts": null,
    "headline": "United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption",
    "summary": "The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable reimbursement policies. Major players: Eli Lilly, Sanofi, Glooko, Medtronic, Novo Nordisk, Owen Mumford. U.S. Insulin Pens Market U.S. Insulin Pens Market Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The \"United States Insulin Pens Market Size, Insights, Competitive Landscape, and Forecast, 2025 - 2033\"",
    "url": "https://finnhub.io/api/news?id=cbe66ed86730d81bb5f64974111a9432c236595402ab1b505b8131983ec7f73c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750845360,
      "headline": "United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption",
      "id": 135527959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable reimbursement policies. Major players: Eli Lilly, Sanofi, Glooko, Medtronic, Novo Nordisk, Owen Mumford. U.S. Insulin Pens Market U.S. Insulin Pens Market Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The \"United States Insulin Pens Market Size, Insights, Competitive Landscape, and Forecast, 2025 - 2033\"",
      "url": "https://finnhub.io/api/news?id=cbe66ed86730d81bb5f64974111a9432c236595402ab1b505b8131983ec7f73c"
    }
  },
  {
    "ts": null,
    "headline": "New data show most US patients now stay on Wegovy, Zepbound after a year",
    "summary": "Nearly two-thirds ofpatients who started on weight-loss drugs Wegovy or Zepboundlast year were still taking them a year later, according to ananalysis of U.S. pharmacy claims. That...",
    "url": "https://finnhub.io/api/news?id=65a0294b0057d14d4096ccd35bb665a3f891b2326ae436b1eab66d58ed8af62e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750843820,
      "headline": "New data show most US patients now stay on Wegovy, Zepbound after a year",
      "id": 135525020,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Nearly two-thirds ofpatients who started on weight-loss drugs Wegovy or Zepboundlast year were still taking them a year later, according to ananalysis of U.S. pharmacy claims. That...",
      "url": "https://finnhub.io/api/news?id=65a0294b0057d14d4096ccd35bb665a3f891b2326ae436b1eab66d58ed8af62e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India and is now prioritizing meeting the demand in the world’s most populous country, with a population of 1.4 billion. Eli Lilly […]",
    "url": "https://finnhub.io/api/news?id=9c703237d74394aba1cca26611690aff1b2797835d621979e072ec63c087d1d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750837655,
      "headline": "Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates",
      "id": 135527960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India and is now prioritizing meeting the demand in the world’s most populous country, with a population of 1.4 billion. Eli Lilly […]",
      "url": "https://finnhub.io/api/news?id=9c703237d74394aba1cca26611690aff1b2797835d621979e072ec63c087d1d8"
    }
  },
  {
    "ts": null,
    "headline": "Victory RS Global Fund Q1 2025 Commentary",
    "summary": "The Victory RS Global Fund returned -4.75% (Class A Shares at net asset value) for the period, while its benchmark, the MSCI All Country World Index (net), returned - 1.32%.",
    "url": "https://finnhub.io/api/news?id=96d0431c664aa3502829c4bba2f5721fcb90ddff14849362e107061eff6d09fe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750837140,
      "headline": "Victory RS Global Fund Q1 2025 Commentary",
      "id": 135524140,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149332829/image_2149332829.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Victory RS Global Fund returned -4.75% (Class A Shares at net asset value) for the period, while its benchmark, the MSCI All Country World Index (net), returned - 1.32%.",
      "url": "https://finnhub.io/api/news?id=96d0431c664aa3502829c4bba2f5721fcb90ddff14849362e107061eff6d09fe"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Inhaled insulin as good as injection for children at mealtime",
    "summary": "Children with diabetes who inhaledtheir mealtime doses of insulin did just as well as those whoinjected insulin under the skin, researchers reported at theAmerican Diabetes Association scientific...",
    "url": "https://finnhub.io/api/news?id=90005cba267623afa23725104dec4a31cb31eb8586a2a050ebfd1a3f0baf6304",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750834882,
      "headline": "Health Rounds: Inhaled insulin as good as injection for children at mealtime",
      "id": 135523893,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Children with diabetes who inhaledtheir mealtime doses of insulin did just as well as those whoinjected insulin under the skin, researchers reported at theAmerican Diabetes Association scientific...",
      "url": "https://finnhub.io/api/news?id=90005cba267623afa23725104dec4a31cb31eb8586a2a050ebfd1a3f0baf6304"
    }
  },
  {
    "ts": null,
    "headline": "Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director",
    "summary": "Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Nicola Heffron as a Non-Executive Director with immediate effect. Nicola has over 25 years of experience across the pharmaceutical and biotech industries, with a focus on rare diseases a",
    "url": "https://finnhub.io/api/news?id=4fb9a7841d5ff75a98e8959e4d247ae9f540f85579783bc581716227ec6e2222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750834800,
      "headline": "Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director",
      "id": 135527961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Nicola Heffron as a Non-Executive Director with immediate effect. Nicola has over 25 years of experience across the pharmaceutical and biotech industries, with a focus on rare diseases a",
      "url": "https://finnhub.io/api/news?id=4fb9a7841d5ff75a98e8959e4d247ae9f540f85579783bc581716227ec6e2222"
    }
  },
  {
    "ts": null,
    "headline": "After key conference, here’s how the race to a $150 billion weight-loss drug market is shaping up",
    "summary": "After key conference, here’s how the race to a $150 billion weight-loss drug market is shaping up",
    "url": "https://finnhub.io/api/news?id=de40f050c3572140917045130b3972418521fedba00cec138677c6ef19561e9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750830180,
      "headline": "After key conference, here’s how the race to a $150 billion weight-loss drug market is shaping up",
      "id": 135539231,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "After key conference, here’s how the race to a $150 billion weight-loss drug market is shaping up",
      "url": "https://finnhub.io/api/news?id=de40f050c3572140917045130b3972418521fedba00cec138677c6ef19561e9b"
    }
  }
]